InMed Welcomes the BayMedica Team – Meet Research Scientist Dr. James Craig!
InMed Pharmaceuticals is pleased to welcome the BayMedica team following its acquisition in October 2021. Meet Dr. James Craig, one of our Research Scientists at...
InMed Welcomes the BayMedica Team – Welcome Dr. Jim Kealey, VP of Synthetic Biology
InMed Pharmaceuticals is pleased to welcome the BayMedica team following its acquisition in October 2021. Meet Dr. Jim Kealey, our VP of Synthetic Biology. Jim...
InMed Welcomes the BayMedica Team! Welcome Dr. Charles Marlowe, VP of Chemistry
InMed Pharmaceuticals is pleased to welcome the BayMedica team following its acquisition in October 2021. Meet Dr. Charles Marlowe, our VP of Chemistry. Chuck talks...
InMed Welcomes the BayMedica Team! Meet Philip Barr, VP of Discovery Research
InMed Pharmaceuticals is pleased to welcome to the BayMedica team following its acquisition in October 2021. Meet Philip Barr, our VP of Discovery Research. Phil...
InMed’s Pharmaceutical Programs in Epidermolysis Bullosa and Glaucoma and Pharma Partnership Opportunities
In this excerpt from The Dales Report interview with host Shadd Dales, InMed's CEO Eric A. Adams talks about the Company's pharmaceutical programs in Epidermolysis...
